Switch theme
Sign up to access all valuation multiples
Zhejiang Shouxiangu Pharmaceutical Co Ltd is a Chinese pharmaceutical company.
2007
n/a
LTM Revenue n/a
LTM EBITDA n/a
$454M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zhejiang Shouxiangu has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Zhejiang Shouxiangu achieved revenue of $108M and an EBITDA of $49.0M.
Zhejiang Shouxiangu expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhejiang Shouxiangu valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $108M | n/a | XXX | XXX | XXX |
| Gross Profit | $88.3M | $96.4M | XXX | XXX | XXX |
| Gross Margin | 82% | NaN% | XXX | XXX | XXX |
| EBITDA | $49.0M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 45% | NaN% | XXX | XXX | XXX |
| Net Profit | $27.7M | $38.3M | XXX | XXX | XXX |
| Net Margin | 26% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zhejiang Shouxiangu's stock price is CNY 19 (or $3).
Zhejiang Shouxiangu has current market cap of CNY 3.9B (or $532M), and EV of CNY 3.3B (or $454M).
See Zhejiang Shouxiangu trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $454M | $532M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zhejiang Shouxiangu has market cap of $532M and EV of $454M.
Zhejiang Shouxiangu's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Zhejiang Shouxiangu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zhejiang Shouxiangu and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $454M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZhejiang Shouxiangu's NTM/LTM revenue growth is n/a
Zhejiang Shouxiangu's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Zhejiang Shouxiangu's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zhejiang Shouxiangu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zhejiang Shouxiangu and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 31% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 54% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Shouxiangu acquired XXX companies to date.
Last acquisition by Zhejiang Shouxiangu was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhejiang Shouxiangu acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Zhejiang Shouxiangu founded? | Zhejiang Shouxiangu was founded in 2007. |
| Where is Zhejiang Shouxiangu headquartered? | Zhejiang Shouxiangu is headquartered in China. |
| Is Zhejiang Shouxiangu publicy listed? | Yes, Zhejiang Shouxiangu is a public company listed on SHG. |
| What is the stock symbol of Zhejiang Shouxiangu? | Zhejiang Shouxiangu trades under 603896 ticker. |
| When did Zhejiang Shouxiangu go public? | Zhejiang Shouxiangu went public in 2017. |
| Who are competitors of Zhejiang Shouxiangu? | Similar companies to Zhejiang Shouxiangu include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Zhejiang Shouxiangu? | Zhejiang Shouxiangu's current market cap is $532M |
| Is Zhejiang Shouxiangu profitable? | Yes, Zhejiang Shouxiangu is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
